Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University Hospital, Grenoble
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients aged 18 or over,
Introducing a single depressive episode or recurrent unipolar
Responding to the diagnosis of severe major depressive episode according to DSM IV (Diagnostic and Statistical Manual of Mental Disorders - Fourth Edition): MADRS score ≥ 20,
absence of treatment with ketamine for analgesia or anesthesia during the last 6 months
Affiliate (or beneficiary) to a social security system
Informed consent signed
You may not be if
Contraindication to ketamine administration or treatment with venlafaxine;
Failure of treatment with venlafaxine in the current episode (as low as 150 mg for 15 days);
Axis I diagnosis according to DSM IV bipolar disorder (type I, II or III), schizoaffective disorder, schizophrenia, alcohol and other toxic or weaned for at least 6 months;
Current Episode resistant stage V according to the classification of Thase and Rush (failed a course of bilateral ECT);
Major depressive episode with severity criteria (significant risk of suicide is a MADRS score ≥ 5-SI; decubitus complications, intravenous hydration);
episode currently being treated with fluoxetine;
Patients hospitalized without their consent or measure of legal protection (guardianship, curatorship);
Affection Organic likely to affect cognitive abilities and brain structures (eg, HIV, MS, lupus, Parkinson's disease, epilepsy, dementia ...) or decompensation;
Pregnancy or breastfeeding underway.
Clareo Health | Estimate the Efficiency of the Association of an Injection of Ketamine and the Venlafaxine in the Severe Major Depressive Disorder for Six Weeks
